第三次肿瘤细胞减灭术在复发性上皮性卵巢癌中的作用:系统综述与Meta分析
该系统综述与Meta分析检索MEDLINE、Embase、ClinicalTrials.gov、Scopus和Web of Science(建库至2021年9月4日),纳入10项观察性研究,评估复发性卵巢癌第三次肿瘤细胞减灭术(TCS)中满意减灭与不满意减灭的生存差异;满意TCS与更好的疾病特异性生存(HR=0.35;95%CI 0.19-0.64,P<0.001)和总生存(HR=0.34;95%CI 0.15-0.74,P<0.007)相关。
要点
- 复发性卵巢癌满意TCS较不满意TCS与更好DSS相关(HR=0.35;95%CI 0.19-0.64)。
- 满意TCS较不满意TCS与更好OS相关(HR=0.34;95%CI 0.15-0.74)。
- 因研究数量有限,未能比较TCS与化疗的结局。
核心结论
- 在复发性卵巢癌第三次肿瘤细胞减灭术的观察性研究系统综述与Meta分析中,满意TCS较不满意TCS与更好的OS和DSS生存相关。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE(via PubMed)、Embase(Elsevier)、ClinicalTrials.gov、Scopus(Elsevier)和Web of Science从建库至2021年9月4日的研究。
- 纳入报告TCS时满意与不满意肿瘤细胞减灭术的疾病特异性生存(DSS)和总生存(OS)的研究,共10项研究符合全部纳入标准。
- 采用预后研究质量(QUIPS)工具评估研究质量,数据由多名观察者独立提取,使用随机效应模型合并关联。
主要发现
- 满意TCS患者较不满意TCS患者DSS更好(HR=0.35;95%CI 0.19-0.64,P<0.001),异质性低(I²=0%,P=0.41)。
- 满意TCS患者较不满意TCS患者OS更好(HR=0.34;95%CI 0.15-0.74,P<0.007),异质性中等(I²=59%,P=0.09)。
- 在一系列敏感性分析中该关联仍显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于研究数量有限,无法进一步进行亚组分析比较TCS与化疗的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical utility of tertiary cytoreductive surgery (TCS) in recurrent ovarian cancer. METHODS: MEDLINE via PubMed, Embase (Elsevier), ClinicalTrials.gov, Scopus (Elsevier) and Web of Science for studies from inception to 4/09/2021. Studies reporting disease specific survival (DSS) and overall survival (OS) among women who underwent optimal cytoreductive surgery as compared to those who had a suboptimal cytoreductive surgery at time of TCS were abstracted. Study quality was assessed with the Quality In Prognosis Studies (QUIPS) tool. The data were extracted independently by multiple observers. Random-effects models were used to pool associations and to analyze the association between survival and surgical outcomes. RESULTS: 10 studies met all the criteria for inclusion in the systematic review. Patients with optimal tertiary cytoreductive surgery had better DSS (HR = 0.35; 95% CI, 0.19-0.64, P < 0.001), with low heterogeneity (I2 = 0%, P = 0.41) when compared to those with suboptimal tertiary cytoreductive surgery. Pooled results from these studies also demonstrated a better OS (HR = 0.34; 95% CI, 0.15-0.74, P < 0.007) with moderate heterogeneity (I2 = 59%, P = 0.09) when compared to patients with a suboptimal tertiary cytoreductive surgery. This remained significant in a series of sensitivity analyses. Due to the limited number of studies, we were unable to do further subgroup analyses looking at outcomes comparing tertiary cytoreductive surgery to chemotherapy. CONCLUSION: In this systematic review and meta-analysis of observational studies examining tertiary cytoreductive surgery for recurrent ovarian cancer, optimal tertiary cytoreductive surgery was associated with improved OS and DSS survival compared to suboptimal tertiary cytoreductive surgery.
引用
- Guida F, Dioun S, Fagotti A, et al. Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis. Gynecol Oncol. 2022. PMID: 35550711. doi:10.1016/j.ygyno.2022.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。